RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

R

Reata, a wholly owned subsidiary of Biogen

Status and phase

Completed
Phase 2

Conditions

MItochondrial Myopathies

Treatments

Drug: omaveloxolone capsules, 160 mg
Drug: omaveloxolone capsules, 80 mg
Drug: omaveloxolone capsules, 10 mg
Drug: omaveloxolone capsules, 20 mg
Drug: omaveloxolone capsules, 5 mg
Drug: Placebo capsules
Drug: Omaveloxolone capsules, 2.5 mg
Drug: omaveloxolone capsules, 40 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT02255422
RTA 408-C-1403

Details and patient eligibility

About

Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently there are no effective treatments for this disease. Despite the heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP), often resulting in muscle weakness, exercise intolerance, and fatigue in patients with mitochondrial myopathies. RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathies. This study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with mitochondrial myopathies.

Full description

Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.

Enrollment

53 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet both):

  • Have a history of exercise intolerance with or without weakness and/or progressive exercise intolerance (in which modest exercise typically provokes heaviness, weakness, aching of active muscles, or tachycardia)
  • Have a known primary mitochondrial DNA mutation or a nuclear DNA defect that is associated with reduced activity of at least 1 mitochondrially encoded respiratory chain complex
  • Be male or female and ≥18 years of age and ≤75 years of age
  • Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
  • Have the ability to complete maximal exercise testing
  • Have a peak workload during maximal exercise testing of ≤ 1.5 W/kg
  • Be able to swallow capsules

Exclusion criteria

  • Have uncontrolled diabetes (HbA1c >11.0%)
  • Have B-type natriuretic peptide level >200 pg/mL
  • Have a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease
  • Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus or hepatitis virus (B or C)
  • Have known or suspected active drug or alcohol abuse
  • Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the upper limit of normal of aspartate aminotransferase, alanine aminotransferase, or creatinine
  • Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment

Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:

  • Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
  • Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
  • Have participated in any other interventional clinical study within 30 days prior to Study Day 1
  • Have a cognitive impairment that may preclude ability to comply with study procedures

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Double Blind

53 participants in 7 patient groups, including a placebo group

omaveloxolone Capsules 2.5 mg and 5 mg
Experimental group
Description:
omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
Treatment:
Drug: Omaveloxolone capsules, 2.5 mg
Drug: omaveloxolone capsules, 5 mg
omaveloxolone Capsules 10 mg
Experimental group
Description:
omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
Treatment:
Drug: omaveloxolone capsules, 10 mg
Placebo Capsules
Placebo Comparator group
Description:
Placebo capsules taken orally once daily for 12 weeks
Treatment:
Drug: Placebo capsules
omaveloxolone Capsules 20 mg
Experimental group
Description:
omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
Treatment:
Drug: omaveloxolone capsules, 20 mg
omaveloxolone Capsules 40 mg
Experimental group
Description:
omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
Treatment:
Drug: omaveloxolone capsules, 40 mg
omaveloxolone Capsules 80 mg
Experimental group
Description:
omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
Treatment:
Drug: omaveloxolone capsules, 80 mg
omaveloxolone Capsules 160 mg
Experimental group
Description:
omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
Treatment:
Drug: omaveloxolone capsules, 160 mg

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems